Teprotumumab combined with glucocorticoid pulse therapy for thyroid-associated ophthalmopathy
10.3980/j.issn.1672-5123.2026.7.26
- VernacularTitle:替妥尤单抗联合糖皮质激素冲击治疗甲状腺相关眼病
- Author:
Yuan LIU
1
;
Qian YANG
1
;
Juan DU
1
;
Hu CHANG
1
;
Ge GAO
1
Author Information
1. Department of Ophthalmology, Baoding No.1 Central Hospital, Baoding 071000, Hebei Province,China
- Publication Type:Journal Article
- Keywords:
teprotumumab;
thyroid-associated ophthalmopathy;
glucocorticoid pulse;
thyroid function
- From:
International Eye Science
2026;26(7):1264-1269
- CountryChina
- Language:Chinese
-
Abstract:
AIM: To explore the clinical therapeutic effect of teprotumumab combined with glucocorticoid pulse therapy for thyroid-associated ophthalmopathy(TAO), and its impacts on thyroid function, levels of inflammatory factors, and adverse reactions in patients. METHODS: Active TAO patients admitted to the Ophthalmology Department were enrolled and randomly divide into the steroid group and the combined group. Then the steroid group was treated with glucocorticoid pulse therapy, while the combined group was combined with intravenous infusion of teprotumumab on the basis of the steroid group. The clinical therapeutic effect, the CAS, OSDI, M-C-TAO-QOL scores, ocular sign indicators(fissure width, proptosis), levels of inflammatory factors(TNF-α, CRP, IL-17), thyroid function(TSH, FT3, FT4)before and after treatment, and occurrence of adverse reactions were compared between two groups.RESULTS:Totally 96 TAO patients(192 eyes)were included, with 48 cases(96 eyes)in each group. In the combined group, there were 17 males and 31 females, with an average age of 51.85±3.53 y; in the steroid group, there were 14 males and 34 females, with an average age of 51.26±3.84 y. The total effective rate of the combined group(94%)was higher than that of the steroid group(79%)(P<0.05). After treatment, the CAS score, OSDI score, fissure width, proptosis, levels of TNF-α, CRP, and IL-17 in the combined group were all lower than those in the steroid group, and the M-C-TAO-QOL score was higher than that in the steroid group(P<0.05). However, there was no difference in thyroid function indicators and adverse reactions between two groups after treatment(P>0.05). CONCLUSION: The combination of teprotumumab and glucocorticoid pulse therapy for TAO has a prominent therapeutic effect. Meantime, it can more effectively control ocular inflammation, improve ocular signs and quality of life of patients, and has no obvious adverse effect on thyroid function, with controllable safety.
